Results 111 to 120 of about 11,074 (164)

First-Line Lorlatinib in Striatin-Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma: A Case Report and Literature Review. [PDF]

Respirol Case Rep
Maebeya M, Tamura S, Shono T, Hoso T, Tatsuta H.   +4 more
europepmc   +1 more source

Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States. [PDF]

Adv Ther
Malhotra J, Marchlewicz EH, Zhang Y, Winer I, Pack K, Danes C, Le HH, Hernandez L.   +7 more
europepmc   +1 more source

ALK-positive large B-cell lymphoma presenting in the nasal cavity with CLTC::ALK fusion: a case report of alectinib-integrated therapy followed by autologous hematopoietic stem cell transplantation. [PDF]

Front Oncol
Yi Q, Chen X, Zhang L.
europepmc   +1 more source

Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement. [PDF]

Front Oncol
Mikalonytė M, Landsbergis V, Kevličius L, Černauskienė S, Davainis L, Žučenka A, Trociukas I, Pileckytė R, Davainienė B, Šlepikienė I, Ražanskienė G, Mickys U, Ražanskas J, Dementavičienė J, Stoškus M, Batiuškaitė R, Griškevičius L.   +16 more
europepmc   +1 more source

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report. [PDF]

Front Oncol
Alsulami A, Almufti R, Eldadah S, Al-Ghamdi Y.   +3 more
europepmc   +1 more source

Monitoring EML4-ALK Biomarkers via a Microfluidic Assay for Treatment Efficacy Assessment. [PDF]

Biosensors (Basel)
Doron S, Brio L, Krasner M, Barbiro-Michaely E, Gerber D.   +4 more
europepmc   +1 more source

Current Management and the New Paradigm for ALK+ NSCLC After CROWN. [PDF]

Cancers (Basel)
Shi S, Christopoulos P.
europepmc   +1 more source

Liver-originated selective autophagy of BTD by alectinib underlies concurrent hepatotoxicity and dermatotoxicity. [PDF]

Autophagy
Huang X, Zhang S, Mu Y, Zhou Y, Chen X, Xia B, Xu Z, Yang X, Yang B, He Q, Yan H, Luo P.   +11 more
europepmc   +1 more source

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival. [PDF]

Oncologist
Liu C, Wang X, Chen L.
europepmc   +1 more source